Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial
Sivaporn Gatechompol, Wonngarm Kittanamongkolchai, Chutitorn Ketloy, Eakchai Prompetchara, Arunee Thitithanyanont, Anan Jongkaewwattana, Supranee Buranapraditkun, Mohamad‐Gabriel Alameh, Sasiwimol Ubolyam, Jiratchaya Sophonphan, Tanakorn Apornpong, Stephen J. Kerr, Adeeba Kamarulzaman, Sarawut Siwamogsatham, Eugène Kroon, Thanyawee Puthanakit, Kanitha Patarakul, Tanapat Palaga, Wassana Wijagkanalan, Alexis Carpenter, Lina Hong, Drew Weissman, Kiat Ruxrungtham, ChulaVAC-001 study team
Topics & Concepts
ImmunogenicityVirologyCoronavirus disease 2019 (COVID-19)Spike (software development)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMessenger RNASpike ProteinVaccine trialPhase (matter)MedicineBiologyGeneImmune systemChemistryImmunologyVaccinationGeneticsComputer scienceOutbreakInfectious disease (medical specialty)Software engineeringDiseasePathologyOrganic chemistrySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral Infections and Immunology Research